Freedom Broker Reiterates Buy Rating on Sanara MedTech

Sanara MedTech Inc. (NasdaqCM: SMTI) received a vote of confidence from Freedom Broker as they reiterated their 'buy' rating with a price target of $35 on June 17, 2026. The stock was trading at $22.74 at the time of the report.

Sanara MedTech Inc. Stock Up 3.8%

Shares of NasdaqCM:SMTI traded near $22.74. Sanara MedTech has a market cap of approximately $194.5 million, sporting a high P/E ratio of 353.67, which suggests high investor expectations. The company's forward P/E is more modest at 39.30. The stock's 52-week range is between $16.05 and $35.95, and it has a beta of 1.188, indicating a slightly higher volatility compared to the market. Moving averages show a 50-day of $20.60 and a 200-day of $23.57.

Recent Earnings

Sanara MedTech reported revenue of $107.5 million, showcasing a growth of 18.6%. However, the company is not yet profitable, with a negative net margin of 31.24%. The return on equity stands at a modest 2.86%. Investors can look forward to the next earnings release on August 13, 2026.

Insider Buying and Selling at Sanara MedTech Inc.

Several insiders made stock purchases on June 4, 2026. Notable transactions include Nixon Ronald, Keith Myers, and Robert Andrew Desutter, who bought 4,154, 4,385, and 5,539 shares respectively. These purchases were not part of any planned trading programs.

Analysts Set New Price Targets

On June 17, 2026, Freedom Broker reiterated a 'buy' rating with a $35 price target. Earlier, on April 15, 2026, Lake Street initiated coverage with a 'buy' rating and a $32 target. The analyst consensus suggests a mean price target of $34, with two analysts currently covering the stock.

About Sanara MedTech

Sanara MedTech Inc., based in Fort Worth, Texas, is a healthcare company specializing in developing and marketing surgical solutions. Their products, such as CellerateRX Surgical and BIASURGE, are designed for wound management and surgical applications. The company, led by CEO Seth D. Yon, employs 108 people and partners with Rochal for antimicrobial product development.

Bottom Line

Freedom Broker's reiterated 'buy' rating and $35 price target underscore continued confidence in Sanara MedTech's potential. The company's innovative medical solutions and strategic partnerships are key factors for investors to watch. As always, remember that these analyst ratings are based on past data and projections, and do not necessarily reflect the current state of the company.